Recruitment Complete

Amyloid Cardiomyopathy

Bayer Identifier:

AG10-202

ClinicalTrials.gov Identifier:

NCT03536767

EudraCT Number:

Not Available

EU CT Number:

Not Available

An Open-Label Extension and Safety Monitoring Study of Patients with Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201

Trial purpose

Key Participants Requirements

Sex

N/A

Age

N/A

Inclusion Criteria

Exclusion Criteria

Trial summary

Enrollment Goal

N/A

Trial Dates

August 2018 - July 2027

Phase

Phase 2

Could I Receive a placebo

N/A

Products

Acoramidis (BAY3684938)

Accepts Healthy Volunteer

N/A

Trial design

An Open-Label Extension and Safety Monitoring Study of Patients with Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201

Trial Type

Interventional

Intervention Type

N/A

Trial Purpose

Treatment

Allocation

N/A

Blinding

N/A

Assignment

N/A

Trial Arms

N/A